|104.80||-1.15||-1.09%||Vol 4.18M||1Y Perf 25.47%|
|Sep 22nd, 2020 16:02 DELAYED|
|0.60 0.57%||- -%|
|Target Price||111.58||Analyst Rating||Strong Buy 1.44|
|Potential %||6.47||Finscreener Ranking||★+ 44.70|
|Insiders Trans % 3/6/12 mo.||-100/-100/-100||Value Ranking||★ 43.28|
|Insiders Value % 3/6/12 mo.||-100/-100/-100||Growth Ranking||★★★+ 57.14|
|Insiders Shares Cnt. % 3/6/12 mo.||-100/-100/-100||Income Ranking||★+ 39.96|
|Market Cap||185.55B||Earnings Rating||Strong Buy|
|Price Range Ratio 52W %||82.14||Earnings Date||21st Oct 2020|
Today's Price Range
5 Year PE Ratio Range
|Earnings History||Estimate||Reported||Surprise %|
|Earnings Per End||Estimate||Revision %||Trend|
|Next Report Date||21st Oct 2020|
|Estimated EPS Next Report||0.89|
|EPS Growth Next 5 Years %||11.00|
|Avg. Weekly Volume||4.74M|
|Avg. Monthly Volume||7.01M|
|Avg. Quarterly Volume||5.23M|
Abbott Laboratories (NYSE: ABT) stock closed at 104.8 per share at the end of the most recent trading day (a -1.09% change compared to the prior day closing price) with a volume of 4.18M shares and market capitalization of 185.55B. Is a component of S&P 500, Russell 1000 indices and it is traded on NYSE exchange. The company belongs in the Medical Devices & Instruments industry, Healthcare sector and employs 103000 people. Abbott Laboratories CEO is Miles D. White.
The one-year performance of Abbott Laboratories stock is 25.47%, while year-to-date (YTD) performance is 20.65%. ABT stock has a five-year performance of 149.78%. Its 52-week range is between 61.61 and 114.19, which gives ABT stock a 52-week price range ratio of 82.14%
Abbott Laboratories currently has a PE ratio of 61.80, a price-to-book (PB) ratio of 6.19, a price-to-sale (PS) ratio of 6.02, a price to cashflow ratio of 29.80, a PEG ratio of 2.32, a ROA of 4.53%, a ROC of 7.07% and a ROE of 9.99%. The company’s profit margin is 9.89%, its EBITDA margin is 23.10%, and its revenue ttm is $31.44 Billion , which makes it $17.76 revenue per share.
Of the last four earnings reports from Abbott Laboratories, there were 2 positive earnings surprise and 0 negative earnings surprise. The company has EPS estimate of $0.89 for the next earnings report. Abbott Laboratories’s next earnings report date is 21st Oct 2020.
The consensus rating of Wall Street analysts for Abbott Laboratories is Strong Buy (1.44), with a target price of $111.58, which is +6.47% compared to the current price. The earnings rating for Abbott Laboratories stock is Strong Buy (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).
Abbott Laboratories has a dividend yield of 1.35% with a dividend per share of $1.44 and a payout ratio of 66.00%.
Abbott Laboratories has a Neutral technical analysis rating based on Technical Indicators (ADX : 23.32, ATR14 : 2.59, CCI20 : -54.89, Chaikin Money Flow : -0.19, MACD : 1.03, Money Flow Index : 38.62, ROC : 0.61, RSI : 50.78, STOCH (14,3) : 31.78, STOCH RSI : 0.00, UO : 51.94, Williams %R : -68.22), Simple Moving Averages and Exponential Moving Averages.
Aggregated Insider Trades of Abbott Laboratories in the last 12-months were: Andrea F. Wainer (Sold 2 549 shares of value $210 549 ), Andrew H. Lane (Option Excercise at a value of $3 505 313), Andrew H. Lane (Sold 80 000 shares of value $7 360 104 ), Brian B. Yoor (Option Excercise at a value of $23 110 673), Brian B. Yoor (Sold 509 850 shares of value $45 747 208 ), Charles R. Brynelsen (Sold 1 781 shares of value $138 722 ), Christopher J. Scoggins (Sold 1 654 shares of value $136 369 ), Daniel Gesua Sive Salvadori (Option Excercise at a value of $1 996 513), Daniel Gesua Sive Salvadori (Sold 43 478 shares of value $4 829 513 ), Hubert L. Allen (Sold 1 208 shares of value $94 091 ), Jaime Contreras (Option Excercise at a value of $6 192 994), Jaime Contreras (Sold 2 001 shares of value $155 858 ), Jared L. Watkin (Sold 10 009 shares of value $813 500 ), John F. Ginascol (Option Excercise at a value of $5 538 464), John F. Ginascol (Sold 69 806 shares of value $6 579 855 ), John M. Capek (Option Excercise at a value of $2 535 691), John M. Capek (Sold 102 400 shares of value $10 653 603 ), Joseph J. Manning (Option Excercise at a value of $1 440 000), Joseph J. Manning (Sold 37 500 shares of value $3 359 411 ), Lisa D. Earnhardt (Sold 872 shares of value $79 216 ), Mary K. Moreland (Sold 1 419 shares of value $124 632 ), Michael D. Dale (Sold 1 183 shares of value $96 532 ), Michael J. Pederson (Option Excercise at a value of $0), Michael J. Pederson (Sold 23 008 shares of value $2 254 784 ), Phebe N. Novakovic (Option Excercise at a value of $187 353), Phebe N. Novakovic (Sold 1 866 shares of value $188 052 ), Philip P. Boudreau (Sold 10 600 shares of value $869 200 ), Randel W. Woodgrift (Option Excercise at a value of $614 400), Randel W. Woodgrift (Sold 28 644 shares of value $2 412 131 ), Robert E. Funck (Option Excercise at a value of $2 673 276), Robert E. Funck (Sold 2 712 shares of value $211 238 ), Roger M. Bird (Sold 6 956 shares of value $735 804 ), Roxanne S. Austin (Sold 13 688 shares of value $1 366 076 )
Copyright (c) 2020. All rights reserved. Before deciding to trade you should carefully consider your investment objectives, level of experience and your risk appetite. Forex and Tradegate data is a real-time with a 30 second refresh. Prices may not be accurate and may differ from the actual market price. Prices on the website are indicative and solely for informational purposes, not for trading purposes or advice. Please be aware of the risks associated with trading the on financial markets, it is one of the riskiest investment forms. Past performance does not guarantee future profits. We take no responsibility for any losses that may arise as a result of the data contained on this website. The content and the website are provided "as is", without any warranties. In no event will Finscreener.com, its employees, owners, directors, affiliates, partners, data provider, third party or anyone else liable to anyone else for any decision made regarding information on this website.
This could take some time, please wait.